Clinical Trial

Study of DONQ52 in Active Celiac Disease

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The main aim is to see how DONQ52 works to improve small intestinal damage and reduce celiac-related symptoms due to gluten exposure, in participants with celiac disease (CeD) attempting to maintain a gluten-free diet (GFD) in treated participants versus placebo controls.
Protocol Amendment History 4 changes
notable Trial sites expanded: 56 -> 62 locations 2026-07-17
notable Trial sites expanded: 38 -> 56 locations 2026-05-21
notable Trial sites expanded: 29 -> 38 locations 2026-04-21
notable Trial sites expanded: 11 -> 29 locations 2026-04-10
Trial Details
NCT Number NCT07239336
Lead Sponsor Chugai Pharmaceutical
Conditions Celiac Disease
Enrollment 92 participants
Start Date 2025-12-16
Primary Completion 2027-06-15 (estimated)
Study Completion 2027-12-15 (estimated)
Updated on ClinicalTrials.gov 2026-07-16